MD-GASTROVIEW
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MD-GASTROVIEW (MD-GASTROVIEW).
Gastrografin (MD-Gastroview) is a water-soluble contrast agent containing diatrizoate meglumine and diatrizoate sodium. It acts by increasing the radiodensity of the gastrointestinal tract, thereby enhancing visualization on imaging studies. Its hyperosmolarity (approximately 1900 mOsm/kg) promotes fluid shift into the bowel lumen, which can also be used therapeutically for adynamic ileus or meconium ileus.
| Metabolism | Diatrizoate is not metabolized and is excreted unchanged primarily via glomerular filtration in the kidneys. A small fraction may be excreted in bile or feces. |
| Excretion | Primarily renal excretion as unchanged drug via glomerular filtration; approximately 90-95% eliminated in urine within 24 hours, with less than 5% eliminated in feces via biliary excretion. |
| Half-life | Terminal elimination half-life: 12-18 hours in patients with normal renal function; prolonged to >24 hours in moderate-to-severe renal impairment (eGFR <30 mL/min). |
| Protein binding | Negligible protein binding (<1%); does not bind significantly to plasma proteins such as albumin or globulins. |
| Volume of Distribution | Volume of distribution: 0.2-0.3 L/kg; reflects distribution primarily within extracellular fluid and minimal tissue penetration. |
| Bioavailability | Oral bioavailability: 100% (poorly absorbed from the gastrointestinal tract; acts as a non-absorbable contrast agent). |
| Onset of Action | Oral administration: radiographic visualization of the GI tract begins within 15-30 minutes; peak enhancement of the stomach and proximal small bowel occurs at approximately 30-60 minutes post-dose. |
| Duration of Action | Radiographic contrast enhancement persists for approximately 2-4 hours for upper GI studies, with colonic opacification detectable for up to 6-8 hours after oral administration. |
Oral: 300 mL of a 0.1% solution (300 mg) administered 30-60 minutes prior to imaging. May be given via nasogastric tube if necessary.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution; consider alternative agent if risk of accumulation (e.g., in dialysis patients). |
| Liver impairment | No formal studies; no specific adjustment recommended. Use with caution in severe hepatic impairment (Child-Pugh class C) due to potential systemic absorption. |
| Pediatric use | Weight-based: 2.5 mL/kg of 0.1% solution (2.5 mg/kg) orally, up to a maximum of 300 mL. For children <10 kg, consider using a lower concentration (e.g., 1% solution diluted as needed). |
| Geriatric use | No specific dose adjustment required. Monitor for aspiration in elderly with swallowing difficulties; consider smaller volumes (e.g., 150-200 mL) if tolerated. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MD-GASTROVIEW (MD-GASTROVIEW).
| Breastfeeding | Barium sulfate is not absorbed from the GI tract; it does not enter maternal circulation or breast milk. M/P ratio not applicable. Considered compatible with breastfeeding. Inadvertent oral ingestion by infant unlikely. |
| Teratogenic Risk | MD-GASTROVIEW (barium sulfate) is not absorbed systemically; no teratogenic effects observed in animal studies. First trimester: low risk. Second trimester: safe. Third trimester: safe, but maternal positioning during procedure should avoid supine hypotension. No known fetal malformations. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to diatrizoate or any iodine-containing contrast agent.","Acute renal failure or severe renal impairment (e.g., eGFR < 30 mL/min).","Decompensated heart failure (due to fluid shifts).","Suspected or known gastrointestinal perforation (use with caution; water-soluble agents may cause mediastinitis).","Concurrent administration with oral metformin due to risk of lactic acidosis; hold metformin for 48 hours post-procedure."]
| Precautions | ["Risk of severe allergic reactions including anaphylaxis, especially in patients with known iodine allergy.","Risk of aspiration pneumonitis if aspirated into lungs; water-soluble agents cause pulmonary edema.","Dehydration and electrolyte disturbances due to hyperosmolarity, particularly in infants and elderly.","Cross-reactivity with shellfish allergy is controversial but caution is advised.","Renal toxicity in patients with pre-existing renal insufficiency; avoid in acute kidney injury or severe chronic kidney disease.","Intravasation leading to systemic toxicity; monitor during administration."] |
Loading safety data…
| Fetal Monitoring |
| Maternal vital signs during procedure. Fetal heart rate monitoring if prolonged or complicated exam. Monitor for maternal aspiration or allergic reaction to additives. No specific fetal monitoring required post-procedure. |
| Fertility Effects | No known effect on fertility. Barium sulfate is not systemically absorbed; no hormonal or gonadal impact. No reproductive toxicity in animal studies. |